BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

Donald A. Berry, Edwin S. Iversen, Daniel F. Gudbjartsson, Elaine H. Hiller, Judy E. Garber, Beth N. Peshkin, Caryn Lerman, Patrice Watson, Henry T. Lynch, Susan G. Hilsenbeck, Wendy S. Rubinstein, Kevin S. Hughes, Giovanni Parmigiani

Research output: Contribution to journalArticle

352 Citations (Scopus)

Abstract

Purpose: To compare genetic test results for deleterious mutations of BRCA1 and BRCA2 with estimated probabilities of carrying such mutations; to assess sensitivity of genetic testing; and to assess the relevance of other susceptibility genes in familial breast and ovarian cancer. Patients and Methods: Data analyzed were from six high-risk genetic counseling clinics and concern individuals from families for which at least one member was tested for mutations at BRCA1 and BRCA2. Predictions of genetic predisposition to breast and ovarian cancer for 301 individuals were made using BRCAPRO, a statistical model and software using Mendelian genetics and Bayesian updating. Model predictions were compared with the results of genetic testing. Results: Among the test individuals, 126 were Ashkenazi Jewish, three were male subjects, 243 had breast cancer, 49 had ovarian cancer, 34 were unaffected, and 139 tested positive for BRCA1 mutations and 29 for BRCA2 mutations. BRCAPRO performed well: for the 150 probands with the smallest BRCAPRO carrier probabilities (average, 29.0%), the proportion testing positive was 32.7%; for the 151 probands with the largest carrier probabilities (average, 95.2%), 78.8% tested positive. Genetic testing sensitivity was estimated to be at least 85%, with false-negatives including mutations of susceptibility genes heretofore unknown. Conclusion: BRCAPRO is an accurate counseling tool for determining the probability of carrying mutations of BRCA1 and BRCA2. Genetic testing for BRCA1 and BRCA2 is highly sensitive, missing an estimated 15% of mutations. In the populations studied, breast cancer susceptibility genes other than BRCA1 and BRCA2 either do not exist, are rare, or are associated with low disease penetrance.

Original languageEnglish
Pages (from-to)2701-2712
Number of pages12
JournalJournal of Clinical Oncology
Volume20
Issue number11
DOIs
StatePublished - Jun 1 2002
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Testing
Breast Neoplasms
Mutation
Ovarian Neoplasms
Penetrance
Genetic Counseling
Statistical Models
Genetic Predisposition to Disease
Genes
Counseling
Software
Population

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Berry, D. A., Iversen, E. S., Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., ... Parmigiani, G. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology, 20(11), 2701-2712. https://doi.org/10.1200/JCO.2002.05.121

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. / Berry, Donald A.; Iversen, Edwin S.; Gudbjartsson, Daniel F.; Hiller, Elaine H.; Garber, Judy E.; Peshkin, Beth N.; Lerman, Caryn; Watson, Patrice; Lynch, Henry T.; Hilsenbeck, Susan G.; Rubinstein, Wendy S.; Hughes, Kevin S.; Parmigiani, Giovanni.

In: Journal of Clinical Oncology, Vol. 20, No. 11, 01.06.2002, p. 2701-2712.

Research output: Contribution to journalArticle

Berry, DA, Iversen, ES, Gudbjartsson, DF, Hiller, EH, Garber, JE, Peshkin, BN, Lerman, C, Watson, P, Lynch, HT, Hilsenbeck, SG, Rubinstein, WS, Hughes, KS & Parmigiani, G 2002, 'BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes', Journal of Clinical Oncology, vol. 20, no. 11, pp. 2701-2712. https://doi.org/10.1200/JCO.2002.05.121
Berry, Donald A. ; Iversen, Edwin S. ; Gudbjartsson, Daniel F. ; Hiller, Elaine H. ; Garber, Judy E. ; Peshkin, Beth N. ; Lerman, Caryn ; Watson, Patrice ; Lynch, Henry T. ; Hilsenbeck, Susan G. ; Rubinstein, Wendy S. ; Hughes, Kevin S. ; Parmigiani, Giovanni. / BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. In: Journal of Clinical Oncology. 2002 ; Vol. 20, No. 11. pp. 2701-2712.
@article{af5139c30bf942ac80e358d7f2f220c7,
title = "BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes",
abstract = "Purpose: To compare genetic test results for deleterious mutations of BRCA1 and BRCA2 with estimated probabilities of carrying such mutations; to assess sensitivity of genetic testing; and to assess the relevance of other susceptibility genes in familial breast and ovarian cancer. Patients and Methods: Data analyzed were from six high-risk genetic counseling clinics and concern individuals from families for which at least one member was tested for mutations at BRCA1 and BRCA2. Predictions of genetic predisposition to breast and ovarian cancer for 301 individuals were made using BRCAPRO, a statistical model and software using Mendelian genetics and Bayesian updating. Model predictions were compared with the results of genetic testing. Results: Among the test individuals, 126 were Ashkenazi Jewish, three were male subjects, 243 had breast cancer, 49 had ovarian cancer, 34 were unaffected, and 139 tested positive for BRCA1 mutations and 29 for BRCA2 mutations. BRCAPRO performed well: for the 150 probands with the smallest BRCAPRO carrier probabilities (average, 29.0{\%}), the proportion testing positive was 32.7{\%}; for the 151 probands with the largest carrier probabilities (average, 95.2{\%}), 78.8{\%} tested positive. Genetic testing sensitivity was estimated to be at least 85{\%}, with false-negatives including mutations of susceptibility genes heretofore unknown. Conclusion: BRCAPRO is an accurate counseling tool for determining the probability of carrying mutations of BRCA1 and BRCA2. Genetic testing for BRCA1 and BRCA2 is highly sensitive, missing an estimated 15{\%} of mutations. In the populations studied, breast cancer susceptibility genes other than BRCA1 and BRCA2 either do not exist, are rare, or are associated with low disease penetrance.",
author = "Berry, {Donald A.} and Iversen, {Edwin S.} and Gudbjartsson, {Daniel F.} and Hiller, {Elaine H.} and Garber, {Judy E.} and Peshkin, {Beth N.} and Caryn Lerman and Patrice Watson and Lynch, {Henry T.} and Hilsenbeck, {Susan G.} and Rubinstein, {Wendy S.} and Hughes, {Kevin S.} and Giovanni Parmigiani",
year = "2002",
month = "6",
day = "1",
doi = "10.1200/JCO.2002.05.121",
language = "English",
volume = "20",
pages = "2701--2712",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes

AU - Berry, Donald A.

AU - Iversen, Edwin S.

AU - Gudbjartsson, Daniel F.

AU - Hiller, Elaine H.

AU - Garber, Judy E.

AU - Peshkin, Beth N.

AU - Lerman, Caryn

AU - Watson, Patrice

AU - Lynch, Henry T.

AU - Hilsenbeck, Susan G.

AU - Rubinstein, Wendy S.

AU - Hughes, Kevin S.

AU - Parmigiani, Giovanni

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Purpose: To compare genetic test results for deleterious mutations of BRCA1 and BRCA2 with estimated probabilities of carrying such mutations; to assess sensitivity of genetic testing; and to assess the relevance of other susceptibility genes in familial breast and ovarian cancer. Patients and Methods: Data analyzed were from six high-risk genetic counseling clinics and concern individuals from families for which at least one member was tested for mutations at BRCA1 and BRCA2. Predictions of genetic predisposition to breast and ovarian cancer for 301 individuals were made using BRCAPRO, a statistical model and software using Mendelian genetics and Bayesian updating. Model predictions were compared with the results of genetic testing. Results: Among the test individuals, 126 were Ashkenazi Jewish, three were male subjects, 243 had breast cancer, 49 had ovarian cancer, 34 were unaffected, and 139 tested positive for BRCA1 mutations and 29 for BRCA2 mutations. BRCAPRO performed well: for the 150 probands with the smallest BRCAPRO carrier probabilities (average, 29.0%), the proportion testing positive was 32.7%; for the 151 probands with the largest carrier probabilities (average, 95.2%), 78.8% tested positive. Genetic testing sensitivity was estimated to be at least 85%, with false-negatives including mutations of susceptibility genes heretofore unknown. Conclusion: BRCAPRO is an accurate counseling tool for determining the probability of carrying mutations of BRCA1 and BRCA2. Genetic testing for BRCA1 and BRCA2 is highly sensitive, missing an estimated 15% of mutations. In the populations studied, breast cancer susceptibility genes other than BRCA1 and BRCA2 either do not exist, are rare, or are associated with low disease penetrance.

AB - Purpose: To compare genetic test results for deleterious mutations of BRCA1 and BRCA2 with estimated probabilities of carrying such mutations; to assess sensitivity of genetic testing; and to assess the relevance of other susceptibility genes in familial breast and ovarian cancer. Patients and Methods: Data analyzed were from six high-risk genetic counseling clinics and concern individuals from families for which at least one member was tested for mutations at BRCA1 and BRCA2. Predictions of genetic predisposition to breast and ovarian cancer for 301 individuals were made using BRCAPRO, a statistical model and software using Mendelian genetics and Bayesian updating. Model predictions were compared with the results of genetic testing. Results: Among the test individuals, 126 were Ashkenazi Jewish, three were male subjects, 243 had breast cancer, 49 had ovarian cancer, 34 were unaffected, and 139 tested positive for BRCA1 mutations and 29 for BRCA2 mutations. BRCAPRO performed well: for the 150 probands with the smallest BRCAPRO carrier probabilities (average, 29.0%), the proportion testing positive was 32.7%; for the 151 probands with the largest carrier probabilities (average, 95.2%), 78.8% tested positive. Genetic testing sensitivity was estimated to be at least 85%, with false-negatives including mutations of susceptibility genes heretofore unknown. Conclusion: BRCAPRO is an accurate counseling tool for determining the probability of carrying mutations of BRCA1 and BRCA2. Genetic testing for BRCA1 and BRCA2 is highly sensitive, missing an estimated 15% of mutations. In the populations studied, breast cancer susceptibility genes other than BRCA1 and BRCA2 either do not exist, are rare, or are associated with low disease penetrance.

UR - http://www.scopus.com/inward/record.url?scp=0036605379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036605379&partnerID=8YFLogxK

U2 - 10.1200/JCO.2002.05.121

DO - 10.1200/JCO.2002.05.121

M3 - Article

VL - 20

SP - 2701

EP - 2712

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -